Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vancheri, Carlo
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF	Terminated	3	372	Europe, US, RoW	Pamrevlumab, FG-3019, Placebo	FibroGen	Idiopathic Pulmonary Fibrosis	09/23	09/23
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF	Active, not recruiting	2	48	Europe, RoW	RXC007, Placebo	Redx Pharma Plc, Simbec-Orion Group	IPF, Fibrosis	06/24	01/25
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	2	150	Europe, Canada, US, RoW	GSK3915393, Placebo	GlaxoSmithKline	Idiopathic Pulmonary Fibrosis	03/26	03/26